Advertisement
Advertisement
-
Business /

Money

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

Hong Kong seeks to hone edge as offshore yuan hub, digital-asset front runner

Market participants largely welcome Paul Chan’s renewed push to strengthen Hong Kong’s position as an international financial centre.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW